Assessment of cell proliferation in renal cell carcinoma using dual‑phase 18F‑fluorodeoxyglucose PET/CT

Onishi,Rei; Noguchi,Masanori; Kaida,Hayato; Moriya,Fukuko; Chikui,Katsuaki; Kurata,Seiji; Kawahara,Akihiko; Kage,Masayoshi; Ishibashi,Masatoshi; Matsuoka,Kei

doi:10.3892/ol.2015.3372

Assessment of cell proliferation in renal cell carcinoma using dual‑phase 18F‑fluorodeoxyglucose PET/CT

Authors:
- Rei Onishi
- Masanori Noguchi
- Hayato Kaida
- Fukuko Moriya
- Katsuaki Chikui
- Seiji Kurata
- Akihiko Kawahara
- Masayoshi Kage
- Masatoshi Ishibashi
- Kei Matsuoka
View Affiliations

Affiliations: Department of Urology, Kurume University School of Medicine, Kurume, Fukuoka 830‑0011, Japan, Division of Nuclear Medicine, PET Center and Department of Radiology, Kurume University School of Medicine, Kurume, Fukuoka 830‑0011, Japan, Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka 830‑0011, Japan
Published online on: June 11, 2015 https://doi.org/10.3892/ol.2015.3372
Pages: 822-828

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to examine the association between 18F‑fluorodeoxyglucose (18F‑FDG) uptake and cell proliferation markers; in addition, the correlation between 18F‑FDG uptake and biological characteristic in patients with renal cell carcinoma (RCC) was investigated using dual‑phase 18F‑FDG‑positron emission tomography/computed tomography (PET/CT). Dual‑phase 18F‑FDG PET/CT was performed on 31 RCC patients and the maximum standardized uptake values at 1 h (SUV1) and 2 h (SUV2) as well as the retention index (RI; %) in the primary tumors were calculated. Monoclonal antibodies for Ki‑67, minichromosome maintenance 2 (MCM2) and topoisomerase II α (topo II α) were used to assess the expression levels of their respective proteins in excised tumor tissue using immunohistochemistry. The results demonstrated that RI and SUV2 in patients with Stage I/II + grade 1 (G1) RCC were significantly decreased compared with all patients with other stages/grades (RI, P=0.0065; SUV2, P=0.043); in addition, significantly increased uptake and RI were detected in patients with metastases compared with patients without metastases (SUV1, P=0.029; SUV2, P=0.0003; RI, P<0.001). All proliferation markers significantly correlated with RI (Ki‑67, r=0.501, P=0.004; MCM2, r=0.359, P=0.047; topo II α, r=0.402, P=0.024), while SUV1 and SUV2 correlated with Ki‑67 only. In conclusion, the results of the present study demonstrated that dual‑phase 18F‑FDG‑PET/CT was more useful for predicting cell proliferation in RCC compared with single‑phase imaging alone. However, follow‑ups are required in order to determine whether dual‑phase 18F‑FDG‑PET/CT provides independent prognostic information.

View Figures

View References

1	Lawrentschuk N, Davis ID, Bolton BM and Scott AM: Functional imaging of renal cell carcinoma. Nat Rev Urol. 7:258–266. 2010. View Article : Google Scholar : PubMed/NCBI
2	Kumar R, Shandai V, Shamim SA, Jeph S, Singh H and Malhotra A: Role of FDG PET-CT in recurrent renal cell carcinoma. Nucl Med Commun. 31:844–850. 2010.PubMed/NCBI
3	Minamimoto R, Nakaigawa N, Tateishi U, et al: Evaluation of response to multikinase inhibitor in metastatic renal cell carcinoma by FDG PET/contrast-enhanced CT. Clin Nucl Med. 35:918–923. 2010. View Article : Google Scholar : PubMed/NCBI
4	Namura K, Minamimoto R, Yao M, Makiyama K, et al: Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: A preliminary report. BMC Cancer. 10:6672010. View Article : Google Scholar : PubMed/NCBI
5	Wang HY, Ding HJ, Chen JH, et al: Meta-analysis of the diagnostic performance of [18F]FDG-PET and PET/CT in renal cell carcinoma. Cancer Imaging. 12:464–474. 2012. View Article : Google Scholar : PubMed/NCBI
6	Mitsudomi T, Hamajima N, Ogawa M and Takahashi T: Prognostic significance of p53 alterations in patients with non-small cell lung cancer: A meta-analysis. Clin Cancer Res. 6:4055–4063. 2000.PubMed/NCBI
7	Gerdes J, Schwab U, Lemke H and Stein H: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 31:13–20. 1983. View Article : Google Scholar : PubMed/NCBI
8	Rodins K, Cheale M, Coleman N and Fox SB: Minichromosome maintenance protein 2 expression in normal kidney and renal cell carcinomas: Relationship to tumor dormancy and potential clinical utility. Clin Cancer Res. 8:1075–1081. 2002.PubMed/NCBI
9	Gianni L, Norton L, Wolmark N, Suter TM, Bonadonna G and Hortobagyi GN: Role of anthracyclines in the treatment of early breast cancer. J Clin Oncol. 27:4798–4808. 2009. View Article : Google Scholar : PubMed/NCBI
10	Albadine R, Wang W, Brownlee NA, et al: Topoisomerase II alpha status in renal medullary carcinoma: Immune-expression and gene copy alterations of a potential target of therapy. J Urol. 182:735–740. 2009. View Article : Google Scholar : PubMed/NCBI
11	Murakami S, Saito H, Sakuma Y, Mizutani Y, et al: Correlation of 18F-fluorodeoxyglucose uptake on positron emission tomography with Ki-67 index and pathological invasive area in lung adenocarcinomas 30 mm or less in size. Eur J Radiol. 75:e62–e66. 2010. View Article : Google Scholar : PubMed/NCBI
12	Sobin LH, Gospodarowicz MK and Wittekind CH: International Union Against Cancer: TNM Classification of Malignant Tumors. 7th. Wiley-Blackwell; Baltimore, MD: pp. 253–257. 2009
13	Fuhrman SA, Lasky LC and Limas C: Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Pathol. 6:655–663. 1982. View Article : Google Scholar
14	Groheux D, Martineau A, Vrigneaud JA, et al: Effect of variation in relaxation parameter value on LOR-RAMLA reconstruction of 18F-FDG PET studies. Nucl Med Commun. 30:926–933. 2009. View Article : Google Scholar : PubMed/NCBI
15	Noguchi M, Yao A, Harada M, et al: Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer. Prostate. 67:933–942. 2007. View Article : Google Scholar : PubMed/NCBI
16	Dooms C, van Baardwijk A, Verbeken E, et al: Association between 18F-fluoro-2-deoxy-d-glucose uptake values and tumor vitality: Prognostic value of positron emission tomography in early stage non-small cell lung cancer. J Thorac Oncol. 4:822–828. 2009. View Article : Google Scholar : PubMed/NCBI
17	Folpe AL, Lyles RH, Sprouse JT, Conrad EU III and Eary JF: (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res. 6:1279–1287. 2000.PubMed/NCBI
18	Watababe Y, Suefuji H, Hirose Y, et al: 18F-FDG uptake in primary gastric malignant lymphoma correlates with glucose transporter-1 and histologic malignant potential. Int J Hematol. 97:43–49. 2013. View Article : Google Scholar : PubMed/NCBI
19	Kim BS and Sung SH: Usefulness of 18F-FDG uptake with clnicopathological and immunohistochemical prognostic factors in breast cancer. Ann Nucl Med. 26:175–183. 2012. View Article : Google Scholar : PubMed/NCBI
20	Nguyen XC, Lee WW, Chung JH, et al: FDG uptake, glucose transporter type 1, and Ki-67 expressions in non-small cell lung cancer: Correlations and prognostic values. Eur J Radiol. 62:214–219. 2007. View Article : Google Scholar : PubMed/NCBI
21	Dekel Y, Frede T, Kugel V, Neumann G, Rassweiler J and Koren R: Human DNA topoisomerase II-alpha expression in laparoscopically treated renal cell carcinoma. Oncol Rep. 14:271–274. 2005.PubMed/NCBI
22	Kankuri M, Söderström K, Pelliniemi T, Vahlberg T, Pyrhönen S and Salminen E: The association of immunoreactive P53 and Ki-67 with T-stage, grade, occurrence of metastases and survival in renal cell carcinoma. Anticancer Res. 26:3825–3833. 2006.PubMed/NCBI
23	Dudderidge TJ, Stoeber K, Loddo M, et al: Mcm 2, Geminin, and Ki-67 define proliferative state and are prognostic markers in renal cell carcinoma. Clin Cancer Res. 11:2510–2517. 2005. View Article : Google Scholar : PubMed/NCBI
24	Cheng G, Torigian DA, Zhuang H and Alavi A: When should we recommend use of dual time-point and delayed time-point imaging techniques in FDG-PET? Eur J Nucl Med Mol Imaging. 40:779–787. 2013. View Article : Google Scholar : PubMed/NCBI
25	Aide N, Cappele O, Bottet P, et al: Efficiency of [18F] FDG PET in characterizing renal cancer and detecting distant metastases: A comparison with CT. Eur J Nucl Med Mol Imaging. 30:1236–1245. 2003. View Article : Google Scholar : PubMed/NCBI
26	Wahl RL, Harney J, Hutchins G and Grossman HB: Imaging of renal cancer using positron emission tomography with 2-deox-2-(18-F)-fluoro-D-glucose: Pilot animal and human studies. J Urol. 146:1470–1474. 1991.PubMed/NCBI
27	Wong PK, Lee ST, Murone C, et al: In vivo imaging of cellular proliferation in renal cell carcinoma using 18F-fluorothymidine PET. Asia Oceania J Nucl Med Biol. 2:3–11. 2014.
28	Higashi T, Saga T, Nakamoto Y, et al: Relationship between retention index in dual phase 18F-FDG PET and hexokinase-II and glucose transporter1 expression in pancreatic cancer. J Nucl Med. 43:173–180. 2002.PubMed/NCBI
29	Zhao S, Kuge Y, Mochizuki T, et al: Biologic correlates of intratumoral heterogeneity in 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor. J Nucl Med. 46:675–682. 2005.PubMed/NCBI
30	Waki A, Kato H, Yano R, et al: The importance of glucose transporter activity as the rate-limiting step of 2-deoxygluoce uptake in tumors cells in vitro. Nucl Med Biol. 25:593–597. 1998. View Article : Google Scholar : PubMed/NCBI
31	Ozülker T, Ozülkar F, Ozbek E and Ozpaçaci T: A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses. Nucl Med Commun. 32:265–272. 2011. View Article : Google Scholar : PubMed/NCBI
32	Ho CL, Chen S, Ho KM, et al: Dual-tracer PET/CT in renal angiomyolipoma and subtypes of renal cell carcinoma. Clin Nucl Med. 37:1075–1082. 2012. View Article : Google Scholar : PubMed/NCBI
33	Chang CC, Cho SF, Chen YW, Tu HP, Lin CY and Chang CS: SUV on dual-phase FDG PET/CT correlates with the Ki-67 proliferation index in patients with newly diagnosed non-Hodgkin lymphoma. Clin Nucl Med. 37:e189–e195. 2012. View Article : Google Scholar : PubMed/NCBI
34	García Vicente AM, Castrejón ÁS, Relea Calatayud F, Muñoz AP, León Martín AA, López-Muñiz IC, et al: 18F-FDG retention index and biologic prognostic parameters in breast cancer. Clin Nucl Med. 37:460–466. 2012. View Article : Google Scholar : PubMed/NCBI
35	Ferda J, Ferdova E, Hora M, Hes O, Finek J, Topolcan O and Kreuzberg B: 18F-FDG-PET/CT in potentially advanced renal cell carcinoma: A role in treatment decisions and prognosis estimation. Anticancer Res. 33:2665–2672. 2013.PubMed/NCBI